Finerenone
|
|
|
- CAS-Nr.
- 1050477-31-0
- Englisch Name:
- Finerenone
- Synonyma:
- Finerenone;BAY 94-8862;Finerone;(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide;BAY948862;Fenaridone;Fenalidone;Non Nilidone;Mr Neri ketone;Finerenone Inn
- CBNumber:
- CB72744895
- Summenformel:
- C21H22N4O3
- Molgewicht:
- 378.42
- MOL-Datei:
- 1050477-31-0.mol
|
Finerenone Eigenschaften
- Siedepunkt:
- 554.7±50.0 °C(Predicted)
- Dichte
- 1.29±0.1 g/cm3(Predicted)
- storage temp.
- -20°C
- L?slichkeit
- DMF: 10 mg/ml DMSO: 3 mg/ml Ethanol: insol PBS (pH 7.2): insol
- pka
- 14.76±0.40(Predicted)
- Aggregatzustand
- solid
- Farbe
- White to off-white
- maximale Wellenl?nge (λmax)
- 255 nm
- InChI
- InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1
- InChIKey
- BTBHLEZXCOBLCY-QGZVFWFLSA-N
- SMILES
- N1C2=C(C(OCC)=NC=C2C)[C@H](C2=CC=C(C#N)C=C2OC)C(C(N)=O)=C1C
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
Finerenone Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Finerenone is a novel mineralocorticoid receptor antagonist that has the effect of delaying the progression of chronic kidney disease. Some people may be aware of two other mineralocorticoid receptor antagonists: the diuretic antihypertensive drug spironolactone, and eplerenone.Finerenone is their cognate derivative and is a third-generation mineralocorticoid receptor antagonist. So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. Finerenone was granted FDA approval on 9 July 2021, followed by the EMA approval on 11 March 2022.
Trademarks
Finerenone is sold under the brand name Kerendia and Firialta.
Mode of action
Finerenone is a Nonsteroidal Mineralocorticoid-Receptor Antagonist. The mechanism of action of finerenone is as a Mineralocorticoid Receptor Antagonist. Finerenone inhibits the effects of mineralocorticoids like aldosterone and cortisol when the MR is overactivated, possibly reducing inflammation and fibrosis in the heart and kidney.
Einzelnachweise
Kolkhof, P., Hartmann, E., Freyberger, A., et al.Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52(8), 642-652 (2021).
DOI:
10.1159/000516213Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Finerenone Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Finerenone Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 243)Lieferanten
- Finerenone (BAY 94-8862)
- BAY948862
- 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-
- (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
- BAY 94-8862
- Finerone
- Mr Neri ketone
- (S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
- Finerenone Inn
- Fenaridone
- Finerenone
- inhibit,cardiorenal,systolic,disease,pressure,Finerenone,diabetes,chronic,type,Inhibitor,kidney,Mineralocorticoid Receptor,oral,nonsteroidal,blood
- (DL)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-
- (4S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxamide (Finerenone Impurity)
- Finerenone API
- Finerenone In-House
- BAY 94-8862 Finerenone
- Fenalidone
- Non Nilidone
- 1050477-31-0
- 11050477-31-0
- chemical
- 1050477-31-0
- API
- 1
